Statutory pediatric informations available for anticancer drugs: Inventory and proposals;Autorisation de mise sur le marché et information pédiatrique pour les médicaments de chimiothérapie des cancers: État des lieux et propositions

Archives de Pediatrie

Volumn 9, Issue 7, 2002, Pages 685-693

  Thouvenel, C ^a   Geny M S ^a   Demirdjian, S ^a   Vassal, G ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Cancer; Chemotherapy; Child; Drug approval; Drug information services

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; BLEOMYCINE BELLON; CARBOPLATIN; CARMUSTINE; CELLTOP; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTARBEL; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; DOXORUBICIN DAKOTA PHARM; DOXORUBICINE ASTA; EPIRUBICIN; ETOPOFOS; ETOPOSIDE; ETOPOSIDE DAKOTA; ETOPOSIDE PIERRE FABRE; FARMORUBICINE; FLUDARABINE; FLUDARABINE PHOSPHATE; FOTEMUSTINE; HYDROXYUREA; IFOSFAMIDE; LOMUSTINE; MELPHALAN; METHOTREXATE; METHOTREXATE BELLON; METHOTREXATE TEVA; MITOXANTRONE; PARAPLATINE; PROCARBAZINE; TENIPOSIDE; THIOTEPA; VINCRISTINE; VINCRISTINE PIERRE FABRE; VINCRISTINE SULFATE;

ARTICLE; CANCER CHEMOTHERAPY; CHILD; CHILD CARE; CHILDHOOD CANCER; DOSE CALCULATION; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG INFORMATION; DRUG TOLERABILITY; HEALTH CARE POLICY; HUMAN; LONG TERM CARE; PRESCRIPTION; PROSPECTIVE STUDY;

EID: 0036067959     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(01)00966-6     Document Type: Article

References (18)

1. Comment mieux développer et utiliser les médicaments en pédiatrie?
2. Paediatric labelling requirements. Implications for pharmacokinetic studies
3. Quoi de neuf en pharmacologie pédiatrique?
4. Pediatric oncology: Regulatory initiatives
5. Résolution du Conseil du 14 décembre 2000 relative aux médicaments pédiatriques
6. Quoi de neuf en oncologie pédiatdque?
7. Conduct of phase I trials in children with cancer
8. Les préparations pédiatriques dans les hôpitaux français
9. The Societé française d'oncologie pédiatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia
10. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: Results of the French NBL 90 study
11. Prognostic study of continuous variables (white blood cell count, peripheral blast cell count, haemoglobin level, platelet count and age) in childhood acute lymphoblastic leukaemia. Analysis of a population of 1545 children treated by the French Acute Lymphoblastic Leukaemia Group (FRALLE)
12. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: A CLCGEORTC report
13. Effectiveness of preoperative chemotherapy in Wilms'tumor: Results of an International Society of Paediatric Oncology (SIOP) clinical trial
14. A limited-sampling method for evaluation of the area under the curve of ultrafilterable carboplatin in children
15. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation
16. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts
17. Phase I trial and pharmacological study of a 3-hour-paclitaxel infusion in children with refractory solid tumours: A SFOP study
18. Phase I study of temozolomide in paediatric patients with advanced cancer